Navigation Links
New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
Date:5/17/2012

WASHINGTON, May 17, 2012 /PRNewswire-USNewswire/ -- Despite increasing budget pressures, countries around the world are making substantial investments in pro-innovation policies and programs to lure the biopharmaceutical research sector away from the U.S., finds a new study released by Battelle Technology Partnership Practice.

The study, commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA), further found that while many countries are cutting public expenditures, they are continuing to expand research and development incentives to attract and grow their biopharmaceutical company presence. Despite the short-term costs associated with these investments, foreign governments recognize the long-term economic benefits.

"In countries around the world, governments clearly recognize the potential benefit that biopharmaceutical research companies offer in terms of economic contributions and job growth – especially in a time when economic growth is so fundamentally needed," said PhRMA President and CEO John J. Castellani. "If the U.S. doesn't take similar pro-innovation policy steps to counter these efforts – such as reauthorization of the Prescription Drug User Fee Act, progress on the Trans-Pacific Partnership, intellectual property incentives such as 12 years of data protection for innovator biologics, and a permanent R&D tax credit – our global leadership in medical innovation is at risk."

A U.S. policy framework to help counter these efforts would provide regulatory certainty, ensure patient choice and access to medicines, and incentivize future research and development, he explained.   

Battelle's report focused on 18 countries and the European Union. These countries were selected because of their interest in growing an innovation economy through pro-innovation policies and programs that can be applied to R&D-intensive sectors such as the biopharmaceutical industry.

For example, other countries are increasingly seeking to make substantial public investments in R&D infrastructure, fostering R&D investment via tax and other research incentives, focusing on attracting and growing talent in related employment fields, ensuring access to capital and fostering public-private partnerships.

In addition, many countries have their own national innovation agenda specifically focusing on biomedical research.

Countries selected include a mix of developed countries with existing biopharmaceutical presence (Australia, Canada, France, Germany, Ireland, Israel, Italy, Japan, Sweden, the United Kingdom, and the EU) and emerging countries that are targeting the sector for new growth (Brazil, Chile, China, Russia, Saudi Arabia, Singapore, South Africa and South Korea).

"Until the early 1990s, Germany was known as 'the world's medicine cabinet,'" said Castellani. "Unless we take steps to support innovative industries at a national level, we too will lose our standing, and with it, our jobs. Without a national biomedical innovation agenda, we're not pitting America up against other countries – we're pitting our states up against like-minded foreign governments. So states with vibrant biopharmaceutical research clusters, like North Carolina and Massachusetts, aren't just competing with each other. They're competing with countries like Singapore."  

In the U.S., the biopharmaceutical sector is a large contributor to our economic landscape, with more than 650,000 direct jobs (supporting a total of nearly 4 million jobs) and an economic output that totals more than $900 billion. Also, the sector accounts for nearly 20 percent of all research and development investment by businesses in America. The impact of the sector goes beyond jobs – over the last decade, biopharmaceutical companies have brought more than 300 new medicines to the patients who need them.

The full report can be found here.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $49.5 billion in 2011 in discovering and developing new medicines.

Find PhRMA Online:

For information on how innovative medicines save lives, visit: http://www.innovation.org

For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org

For information on ensuring the flow of medicines during public health emergencies, visit http://www.rxresponse.org


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 26, 2016 Story ... operating models within the health care industry is causing ... efficiency , Deloitte offers a suite of solutions ... issues impacting efficient cost optimization: labor resource analysis, revenue ... services facilitate better outcomes and better economics ...
(Date:6/24/2016)... Mass. , June 24, 2016   ... Spaulding Rehabilitation Network,s Dean Center for Tick ... Physical Medicine and Rehabilitation, MIT Hacking Medicine, University ... for Innovation, today announced the five finalists of ... for Lyme disease.  More than 100 scientists, clinicians, ...
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
Breaking Medicine Technology:
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
Breaking Medicine News(10 mins):